Lucid Diagnostics a commercial-stage, cancer prevention medical diagnostics company, has contracted with the World Trade Center Health Program (WTCHP) to provide the EsoGuard Esophageal DNA test as a covered benefit to the more than 120,000 responders and survivors who participate in the program.
The World Trade Center Health Program provides medical monitoring and treatment to those directly affected by the 9/11 terrorist attacks, including members of the Fire Department of the City of New York (FDNY) and other emergency responders at the World Trade Center, recovery and cleanup workers and those who were in the New York City Disaster Area on September 11, 2001, or in the months that followed.
EsoGuard is now reimbursable at $2,475.81 per test prescribed by clinicians at one of WTCHP’s Clinical Centers of Excellence.
“We are grateful for the opportunity to provide EsoGuard esophageal precancer testing to those affected by the devastating 9/11 terrorist attacks,” said Lishan Aklog, MD, Lucid’s Chairman and chief executive officer. “As a result of their exposure to dust, smoke, and debris, these heroes are at increased risk of developing cancer, just as firefighters are in general. In fact, nearly 35,000 have already been certified as suffering from gastroesophageal reflux disease (GERD), and therefore are at increased risk of developing esophageal cancer. Lucid remains deeply committed to expanding patient access to EsoGuard testing, with the ultimate goal of preventing esophageal cancer and cancer deaths. We look forward to offering EsoGuard testing to WTCHP participants through dedicated #CheckYourFoodTube Precancer Testing events in the New York metropolitan area. This new program is the product of our ongoing, intensive efforts to drive coverage for EsoGuard testing through direct contracting initiatives.”
Further reading: Lucid Diagnostics Launches Next-Gen Esophageal DNA Test